ATyr Pharma Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AP</div>
LIFE -- USA Stock  

USD 4.03  0.11  2.81%

Whilst many millenniums are getting more into healthcare space, it makes sense to digest ATyr Pharma. Why are we still confident in anticipation of a complete recovery. Is current the firm value sustainable? We will go over ATyr Pharma valuation drivers to give you a better outlook on taking a position in it.
Published over a month ago
View all stories for ATyr Pharma | View All Stories
Is ATyr Pharma (NASDAQ:LIFE) valuation viable?
ATyr Pharma currently holds 5.5 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest ATyr Pharma is not taking enough advantage from borrowing. We provide trade advice to complement the prevailing expert consensus on ATyr Pharma. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of ATyr Pharma using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of ATyr Pharma based exclusively on its fundamental and basic technical indicators. By analyzing ATyr Pharma's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of ATyr Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of ATyr Pharma. We calculate exposure to ATyr Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ATyr Pharma's related companies.

ATyr Pharma Investment Alerts

ATyr Pharma investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring ATyr Pharma performance across your portfolios.Please check all investment alerts for ATyr Pharma

ATyr Pharma Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare ATyr Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ATyr Pharma competition to find correlations between indicators driving the intrinsic value of ATyr Pharma.

How ATyr Pharma utilizes its cash?

To perform a cash flow analysis of ATyr Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ATyr Pharma is receiving and how much cash it distributes out in a given period. The ATyr Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. ATyr Pharma Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (18.01 Million)

Breaking down ATyr Pharma Indicators

The entity reported the previous year's revenue of 8.55 M. Net Loss for the year was (17.27 M) with loss before overhead, payroll, taxes, and interest of (13.63 M).
 2017 2018 2019 2020 (projected)
Current Assets86.98 M50.8 M31.93 M49.55 M
Total Assets89.36 M52.75 M36.19 M56.17 M

Margins Breakdown

ATyr Pharma profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or ATyr Pharma itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of ATyr Pharma profit margins.
EBITDA Margin(51.17)
Gross Margin0.89
Profit Margin(54.31)


ATyr Pharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. ATyr Pharma Net Income Per Employee is decreasing over the last 5 years. Furthermore, ATyr Pharma Earnings Before Interest Taxes and Depreciation Amortization USD is rather stable at the moment. ATyr Pharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA is rather stable at the moment. ATyr Pharma Net Income Per Employee is rather stable at the moment. Furthermore, ATyr Pharma Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. The previous year's value of ATyr Pharma Earnings Before Interest Taxes and Depreciation Amortization USD was -23,992,553.

Will ATyr Pharma growth be sustainable after the surge?

Variance is down to 21.65. It may indicate a possible volatility dip. ATyr Pharma shows above-average downside volatility for the selected time horizon. We advise investors to inspect ATyr Pharma further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ATyr Pharma future alpha.

Our Final Perspective on ATyr Pharma

Although many other companies under the biotechnology industry are still a bit expensive, ATyr Pharma may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current ATyr Pharma valuation and our trade advice on ATyr Pharma is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ATyr Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of ATyr Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com